-

01:07:06 AM

LIVE Real Time VBLT Stock Market News

VBLT - Vascular Biogenics Ltd

04/14/21 6:00 AM

Nasdaq : VBLT

Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants

Vascular Biogenics Ltd. ("VBL Therapeutics" or the "Company") (NASDAQ: VBLT), today announced the closing of its underwritten public offering of 6,901,790 ordinary shares, and, to certain investors in lieu thereof, pre-funded warrants to

RHEA-AI

neutral

04/09/21 8:58 AM

Nasdaq : VBLT

Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants

Vascular Biogenics Ltd. ("VBL Therapeutics" or the "Company") (NASDAQ: VBLT), today announced the pricing of an underwritten public offering of 5,150,265 ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to purchase

RHEA-AI

neutral

04/08/21 4:05 PM

Nasdaq : VBLT

Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Vascular Biogenics Ltd. ("VBL Therapeutics" or the "Company") (NASDAQ: VBLT), today announced that it intends to offer and sell ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to purchase ordinary shares in an

RHEA-AI

neutral

03/30/21 7:00 AM

Nasdaq : VBLT

VBL Therapeutics to Host Virtual R&D Day on April 6

VBL Therapeutics (Nasdaq: VBLT) today announced that it will host a virtual R&D Day for analysts and investors beginning at 10:00am ET on Tuesday, April 6, 2021. The event will include presentations from Professor Dror Harats, M.D, Chief

RHEA-AI

neutral

03/25/21 7:00 AM

Nasdaq : VBLT

VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Conference Call and Webcast at 8:30 a . m . EDT Today Continued progress in OVAL Phase 3 registration enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer; high CA-125 response rates (RR) of over 50% in the total evaluable patient population with more than 200

RHEA-AI

positive

03/17/21 7:00 AM

Nasdaq : VBLT

VBL Therapeutics to Report Fourth Quarter and Full Year Financial Results on March 25

VBL Therapeutics (Nasdaq: VBLT) will release its fourth quarter and full year results for the period ended December 31, 2020 on Thursday, March 25, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief

RHEA-AI

neutral

03/08/21 7:00 AM

Nasdaq : VBLT

VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences

VBL Therapeutics (Nasdaq: VBLT) today announced the Company will participate in the following upcoming virtual investor conferences: H.C Wainwright Global Life Sciences Conference Tuesday, March 9, 2021 Presentation available on-demand

RHEA-AI

neutral

03/04/21 7:00 AM

Nasdaq : VBLT

VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics (Nasdaq: VBLT) today announced the online publication of positive results of the pre-specified interim

RHEA-AI

positive

03/01/21 7:00 AM

Nasdaq : VBLT

VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

VBL Therapeutics (Nasdaq: VBLT) today announced that patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec (VB-111) for the

RHEA-AI

neutral

02/22/21 7:00 AM

Nasdaq : VBLT

VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer. The

RHEA-AI

neutral